Mixed infection by Clostridium difficile in an in vitro model of the human gut (Q56833316)

1

0 references

G. S. Crowther

2

0 references

S. L. Todhunter

3

0 references

C. H. Chilton

5

0 references

W. N. Fawley

6

0 references

M. H. Wilcox

Journal of Antimicrobial Chemotherapy

7

0 references

language of work or name

English

0 references

publication date

25 January 2013

0 references

published in

0 references

volume

68

0 references

issue

5

0 references

page(s)

1139-1143

0 references

cites work

The economic burden of Clostridium difficile

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS529

Recurrence of symptoms in Clostridium difficile infection--relapse or reinfection?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS529

Coexistence of multiple multilocus variable-number tandem-repeat analysis subtypes of Clostridium difficile PCR ribotype 027 strains within fecal specimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS529

Clostridium difficile mixed infection and reinfection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS529

Effects of piperacillin/tazobactam on Clostridium difficile growth and toxin production in a human gut model

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS529

Tolevamer is not efficacious in the neutralization of cytotoxin in a human gut model of Clostridium difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS529

Models for the study of Clostridium difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS529

Evidence to support the existence of subgroups within the UK epidemic Clostridium difficile strain (PCR ribotype 1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS529

Emergence of reduced susceptibility to metronidazole in Clostridium difficile

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS529

Use of highly discriminatory fingerprinting to analyze clusters of Clostridium difficile infection cases due to epidemic ribotype 027 strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS529

Validation of a Three-Stage Compound Continuous Culture System for Investigating the Effect of Retention Time on the Ecology and Metabolism of Bacteria in the Human Colon

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS529

Effect of metronidazole on growth and toxin production by epidemic Clostridium difficile PCR ribotypes 001 and 027 in a human gut model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS529

Effects of cefotaxime and desacetylcefotaxime upon Clostridium difficile proliferation and toxin production in a triple-stage chemostat model of the human gut.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS529

Ertapenem pharmacokinetics and impact on intestinal microflora, in comparison to those of ceftriaxone, after multiple dosing in male and female volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS529

Prospective study of the risk of Clostridium difficile diarrhoea in elderly patients following treatment with cefotaxime or piperacillin-tazobactam

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS529

Evaluation of NVB302 versus vancomycin activity in an in vitro human gut model of Clostridium difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS529

A pilot study of rapid benchtop sequencing of Staphylococcus aureus and Clostridium difficile for outbreak detection and surveillance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS529